Clinical Trial Search

Primary: Percentage of Participants With Progression to Lower Respiratory Tract Infection (LRI) — 8; 30; 10 percentage of participants

Primary: Number of Hospital Admissions by Respiratory Syncytial Virus Infection — 2 participants

Primary: Frequency of Adverse Events — 41 participants

Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade - (RSV-seropositive Participants) — 8; 5; 0; 0 Participants

Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade (RSV-seropositive Participants) — 10; 9; 4; 0 Participants

Primary: Host Response to RSV Challenge Measured as Change From Baseline of Chemical Mediators in Nasal Fluid — 23 Participants

Primary: Area Under the Curve (AUC) for RSV-A Memphis 37b Viral Load Determined by Quantitative Real Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) — 350.99…

Primary: Frequency of Grade 1 or Higher Solicited Adverse Events (AEs) by Grade — 14; 7; 27; 11 Participants

Primary: Circulating RI-001 Titer — 9.24; 4.85; 1.42 Fold Change

Primary: Characterization of Participants With Risk Factors for Respiratory Syncytial Virus (RSV) Infection — 134; 449; 46; 160 participants

Primary: Occurrences of Pneumonia — 4; 3 Participants

Primary: Respiratory Syncytial Virus (RSV) Viral Load-time Curve From Immediately Prior to First Dose of JNJ-53718678 Through Day 5 (AUC [Day 1-5]) — 26.13; 25.10 log10…

Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade — 16; 10; 0; 0 Participants

Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade — 17; 9; 3; 1 Participants

Primary: Safety and Tolerability of MEDI8897 as Assessed by the Occurrence of All Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)…

Primary: Duration of Hospital Stay — 3.9; 2.1 days

Primary: Number of Solicited and Unsolicited Adverse Events (AEs) — 17 adverse events

Primary: Percentage of Placebo Receiving Pediatric Participants With Vaccine Virus Detected in Nasal Swabs After the First Vaccination — 0; 0; 0; 0 percentage of participants

Primary: Time-Weighted Average Change in Respiratory Syncytial Viral (RSV) Load From Baseline to Day 5 — -0.77; -0.89 log10 copies/mL — p=0.46

Primary: Percentage of Participants With Asthma at 6 Years of Age: Overall and by Prognostic Factor — 6.1; 11.2; 3.1; 9.6 percentage of participants

Primary: Part A: Serum Concentration of Suptavumab Over Time — 280; 177; 145; 128 mg/L

Primary: Number of Injections Per Patient Per Season — 3.8; 3.9; 4.0; 1.0 Injections administered

Primary: Incidence of RSV Hospitalization (Includes Deaths by RSV) — 62; 46 Participants

Primary: Incidence Rates of First Episode of Respiratory Syncytial Virus (RSV) Respiratory Tract Infection (RTI) [Period 1] — 7.93 Cases per 100 person-years

Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade — 21; 22; 11; 1 Participants

Primary: Number of Subjects With Any Solicited Local Adverse Events (AEs) During a 7-day Follow-up Period After the First Vaccination (Administered at Day 1) — 5; 6; 0; 22…

Primary: Participants With Detectable RSV Shedding in Nasopharyngeal Wash — 2; 4 Participants

Primary: Area Under the Viral Load-Time Curve (VL-AUC) of Respiratory Syncytial Virus (RSV) by Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR) — 0; 236…

Primary: Number of Participants With Adverse Events — 99 Participants

Primary: Percentage of Participants With RSV Hospitalization — 0.0 percentage of participants